Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
MSD Files for Japan Approval of Once-Daily HIV Combo Pill
MSD said on July 11 that it has filed for regulatory approval in Japan for MK-8591A, a once-daily oral HIV treatment combining the investigational agent islatravir and doravirine, a compound already available under the brand name of Pifeltro (doravirine). Islatravir,…
To read the full story
Related Article
BUSINESS
- Nippon Kayaku, GlycoNex Ink Pact on Next-Gen ADC Candidate
March 24, 2026
- Celltrion Wins First Xolair Biosimilar Approval in Japan, Targets May Listing
March 24, 2026
- Roche-Chugai Drops Emugrobart for SMA, FSHD; Obesity Program to Continue
March 24, 2026
- Santen Eyes Pterygium Drug as Key Pipeline Asset, 4 Million Potential Patients in Japan
March 23, 2026
- Chugai Files Device Component of Ranibizumab Eye Implant in Japan
March 23, 2026
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…